Suplatast tosilate (IPD), a new immunoregulator, is effective in vitiligo treatment.
The major type of vitiligo is considered to be an autoimmune disorder. Anti-melanocyte antibodies are frequently detected in sera of patients with this disease. Interleukin (IL)-4 released from Th2 cells is an important factor in stimulating autoantibody production by B-cells. In this study, seven patients with vitiligo treated with suplatast tosilate (IPD), three showed repigmentation and improvement of their lesions after administration of the drug. IPD halted the continuous spread of the lesions in three of the other patients, and, in two of them, also reduced microsome test and thyroid test titers. The efficacy of IPD in treating vitiligo was thought to be due to the suppressive effect of this drug on IL-4 production. No side effect was observed. Thus IPD may represent a new alternative in vitiligo treatment due to its inhibition of autoimmunity by the suppression of IL-4.
Nihei
Y
Y
Department of Dermatology, Fukushima Medical College, Japan.
Nishibu
A
A
Kaneko
F
F
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D018926:Anti-Allergic Agents / Q000008:administration & dosage*; D001190:Arylsulfonates / Q000008:administration & dosage*; D001323:Autoantibodies / Q000187:drug effects*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015847:Interleukin-4 / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013452:Sulfonium Compounds / Q000008:administration & dosage*; D014820:Vitiligo / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology
D018926:Anti-Allergic Agents; D001190:Arylsulfonates; D001323:Autoantibodies; D013452:Sulfonium Compounds; D015847:Interleukin-4; C073028:suplatast tosilate